A5014281693- Systemic Sclerosis and Related Diseases
- Systemic Lupus Erythematosus Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Atherosclerosis and Cardiovascular Diseases
- Pulmonary Hypertension Research and Treatments
- Inflammatory Myopathies and Dermatomyositis
- Dermatologic Treatments and Research
- Mast cells and histamine
- Monoclonal and Polyclonal Antibodies Research
- Rheumatoid Arthritis Research and Therapies
- Connective Tissue Growth Factor Research
- Autoimmune Bullous Skin Diseases
- Eosinophilic Disorders and Syndromes
- Cytokine Signaling Pathways and Interactions
- Medical Imaging and Pathology Studies
- Peripheral Neuropathies and Disorders
- T-cell and B-cell Immunology
- Eosinophilic Esophagitis
- Diagnosis and Treatment of Venous Diseases
- Autoimmune and Inflammatory Disorders Research
- Venous Thromboembolism Diagnosis and Management
- Renal Diseases and Glomerulopathies
- Vasculitis and related conditions
- Cardiovascular Disease and Adiposity
- Liver Disease Diagnosis and Treatment
St Vincent's Hospital
2016-2025
The University of Melbourne
2016-2025
Institute for Musculoskeletal Health
2024-2025
The University of Sydney
2024-2025
Royal Prince Alfred Hospital
2012-2025
St. Vincent's Hospital
2010-2024
St. Vincent's Birmingham
2012-2024
Saint Vincent's Catholic Medical Center
2013-2024
University of Southern Denmark
2023
University of Alberta
2023
Aims Treating to low disease activity is routine in rheumatoid arthritis, but no comparable goal has been defined for systemic lupus erythematosus (SLE). We sought define and validate a Lupus Low Disease Activity State (LLDAS). Methods A consensus definition of LLDAS was generated using Delphi nominal group techniques. Criterion validity determined by measuring the ability attainment, single-centre SLE cohort, predict non-accrual irreversible organ damage, measured Systemic International...
Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but has been lacking. Previously, an international task force consisting representatives medical specialists published framework such definition, without reaching final recommendation. Methods Several systematic literature reviews were performed specific research questions examined suitably chosen data sets. The findings discussed, reformulated...
Objective To determine mortality and causes of death in a multinational inception cohort subjects with systemic sclerosis (SSc). Methods We quantified as standardized ratio (SMR), years life lost, percentage the first decade disease. The comprised recruited within 4 disease onset. For comparison, we used prevalent cohort, which included all irrespective duration at recruitment. determined single primary cause (SSc related or non–SSc related) using case report form, evaluated predictors...
The prevalence of antibodies to RNA polymerase III (anti-RNAP) differs among systemic sclerosis (SSc) cohorts worldwide. Previously reported associations anti-RNAP include diffuse cutaneous disease, tendon friction rubs and renal crisis, with recent reports suggesting a close temporal association between malignancy SSc disease onset patients anti-RNAP. Patients were tested for the presence at recruitment into Australian Scleroderma Cohort Study. We used univariate multivariable methods...
Abstract Objective Selection of flare as the primary outcome variable in systemic lupus erythematosus (SLE) clinical trials fails to capture patients with persistently active disease (PAD). We sought elucidate frequency and determinants PAD. Methods Prospectively collected data from Toronto Lupus Cohort were used determine incidence PAD 2004 2005. Flare was defined an increase SLE Disease Activity Index 2000 update (SLEDAI‐2K) score ≥4 previous visit. a SLEDAI‐2K ≥4, excluding serology...
Systemic lupus erythematosus (SLE) is associated with significant impairment of health-related quality life (HR-QoL). Recently, meeting a definition low disease activity state (LLDAS), analogous to in rheumatoid arthritis, was preliminarily validated as protection from damage accrual. The LLDAS has not been previously evaluated for association patient-reported outcomes. objective this study determine whether better HR-QoL, and examine predictors large multiethnic, multinational cohort...
To determine factors associated with damage accrual in a prospective cohort of patients SLE.Patients SLE who attended the Lupus Clinic at Monash Health, Australia, between 2007 and 2013 were studied. Clinical variables included disease activity (Systemic Erythematosus Disease Activity Index-2K, SLEDAI-2K), time-adjusted mean SLEDAI, cumulative glucocorticoid dose organ International Collaborating Clinics Damage Index (SDI)). Multivariate logistic regression analyses performed to identify...
<h3>Objective:</h3> To determine whether peripheral blood gene expression of patients with systemic lupus erythaematosus (SLE) correlates disease activity measured using the SLE Disease Activity Index 2000 (SLEDAI-2K). <h3>Methods:</h3> RNA was isolated from 269 and profiled on a custom microarray. Hierarchical clustering heat map were used to categorise samples into major clusters based pattern. Correlates, including demographic disease-related characteristics such as SLEDAI-2K score,...
Abstract Introduction Pulmonary arterial hypertension is a major cause of mortality in systemic sclerosis. N-terminal pro-brain natriuretic peptide (NT-proBNP) has emerged as candidate biomarker that may enable the early detection sclerosis-related pulmonary (SSc-PAH). The objective our study was to incorporate NT-proBNP into screening algorithm for SSc-PAH could potentially replace transthoracic echocardiography (TTE) more convenient and less costly "first tier" test. Methods levels were...
Abstract Introduction Pulmonary arterial hypertension (PAH) is a major cause of mortality in connective tissue disease (CTD). We sought to quantify survival and determine factors predictive cohort patients with CTD-associated PAH (CTD-PAH) the current era advanced therapy. Methods Patients right heart catheter proven CTD-PAH were recruited from six specialised treatment centres across Australia followed prospectively. Using methods including Cox proportional hazards regression, we modelled...
Vitamin D status varies with geographic location and no studies of vitamin in systemic lupus erythematosus (SLE) have been reported the Southern Hemisphere.To assess prevalence deficiency an Australian SLE cohort, its relationship disease activity.Data were collected prospectively on 119 consecutive patients Monash Lupus Clinic Melbourne, Australia, between January 2007 2013. Patients had simultaneous serum 25-hydroxyvitamin concentration activity (SLEDAI-2K) recorded. Statistical methods...
Previous studies have shown that traditional risk factors such as hypercholesterolemia and hypertension account for only a small proportion of the dramatically increased atherosclerotic coronary artery disease (CAD) in systemic lupus erythematosus (SLE). However, these studies, exposure to was measured at baseline. In this study, our objective compare measures cumulative with remote recent values each total cholesterol (TC), systolic (SBP), diastolic (DBP) blood pressure terms ability...
Pulmonary arterial hypertension (PAH) is the leading cause of death in systemic sclerosis (SSc). Annual screening with echocardiogram (ECHO) recommended. We present methodological aspects a PAH programme large Australian SSc cohort, epidemiology SSc-PAH this and an evaluation factors influencing physician adherence to guidelines. Patient characteristics results were determined all patients enrolled longitudinal cohort study. Adherence guidelines was assessed by survey rheumatologists....
Abstract Introduction Pulmonary arterial hypertension (PAH) is a major cause of mortality in systemic sclerosis (SSc). Screening guidelines for PAH recommend multiple investigations, including annual echocardiography, which together have low specificity and may not be cost-effective. We sought to evaluate the predictive accuracy serum N-terminal pro-brain natriuretic peptide (NT-proBNP) combination with pulmonary function tests (PFT) (‘proposed’ algorithm) screening algorithm SSc-PAH....
We evaluated the discriminant capacity of Lupus Low Disease Activity State (LLDAS) in post-hoc analysis data from BLISS-52 and BLISS-76 trials belimumab systemic lupus erythematosus (SLE).LLDAS attainment, discrimination between placebo arms, effects subgroups with high disease activity at recruitment were week 52 using appropriate descriptive statistics, χ2 test logistic regression.At 52, for 10 mg/kg, 17.0% 19.3% patients who achieved a Systemic Erythematosus Responder Index-4 also...